[The possibility of the use of several clinical, genetic and MRI characteristics for the prognosis of effects of beta-interferon-1beta treatment in multiple sclerosis].
Recently, beta-interferons have become the first line medicine of pathogenic treatment of multiple sclerosis (MS). 75 MS patients from Moscow received the treatment with beta-interferon-1b (betaferon). Clinical, genetic and MRI data on 48 of them were included in detailed statistical analyses. High basic frequency of relapses, absence of atrophy of the brain at the first MRI scans and the presence of HLA-DRB1*15 (less significant DRB1*0301 and DRB1*04) were associated with better clinical effects of one year Betaferon course--decrease of relapses frequency and delay in EDSS progression.
Boĭko
A N
AN
Khachanova
N V
NV
Buglak
A V
AV
Demina
T L
TL
Beliaeva
I A
IA
Lashch
N V
NV
Serkov
S V
SV
Gusev
E I
EI
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D001921:Brain / Q000473:pathology*; D005260:Female; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D011379:Prognosis; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C553502:HLA-DRB1*03:01 antigen; D016899:Interferon-beta
Vozmozhnost' ispol'zovaniia klinicheskikh, geneticheskikh pokazateleĭ i dannykh magnitno-rezonansnoĭ tomografii dlia prognozirovaniia éffektov lecheniia beta-interferonom-1-beta rasseiannogo skleroza.